Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach.
Blandini
Fabio
F
Laboratory of Functional Neurochemistry, Neurological Institute C. Mondino, Pavia, Italy. fabio.blandini@mondino.it
D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D020820:Dyskinesias / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy*; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000378:metabolism*
D000978:Antiparkinson Agents; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1; D007980:Levodopa